REFRACTORY HEPATOCELLULAR CARCINOMA
Clinical trials for REFRACTORY HEPATOCELLULAR CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HEPATOCELLULAR CARCINOMA trials appear
Sign up with your email to follow new studies for REFRACTORY HEPATOCELLULAR CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on Hard-to-Treat liver cancer
Disease control TerminatedThis early-phase trial tests a new treatment called RPCAR01 for people with advanced liver cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein call…
Matched conditions: REFRACTORY HEPATOCELLULAR CARCINOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for kids with rare cancers: drug targets tumor growth
Disease control OngoingThis phase 2 trial tests the drug cabozantinib in children and young adults with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. Cabozantinib works by blocking enzymes that help tumors grow and form blood vessels. The study a…
Matched conditions: REFRACTORY HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC